NCT06758037 2025-03-18
HiR+X
First Affiliated Hospital of Ningbo University
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05182957 2023-01-31
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03365791 2022-05-27
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis
Phase 2 Completed
NCT05254899 2022-02-24
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
Phase 2 Unknown
NCT05149170 2021-12-08
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
ChineseAMS
Phase 2 Unknown
NCT02677155 2021-03-01
Lymvac-2
Oslo University Hospital
Phase 2 Completed
NCT04676789 2020-12-21
SPENT
Sun Yat-sen University
Phase 2 Unknown
NCT04279379 2020-05-07
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT04096690 2020-03-11
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
Ruijin Hospital
Phase 2 Unknown